[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355627-105":59,"doc-detail-355627-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-bispecific-nanobody-drug-conjugate-targeting-trop2-and-c-met-for-low-concentration-single-dose-treatment-of-pancreatic-cancer","A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer","","Pancreatic cancer remains highly lethal, with limited effective therapies and major obstacles for antibody-drug conjugates (ADCs), including heterogeneous antigen expression and poor tumor penetration. To overcome these constraints, the study develops B6ADC, a nanobody-based bispecific ADC that simultaneously targets TROP2 and c-Met. Preclinical experiments show potent in vitro cytotoxicity across TROP2/c-Met-expressing cancer cell lines and superior in vivo tumor inhibition versus single-target ADC combinations. A single low-dose administration (2.2 mg/kg) eradicates giant tumors, with a favorable safety profile and improved selectivity for dual-positive or weakly positive tumors, supporting a promising strategy for pancreatic cancer and related malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-bispecific-nanobody-drug-conjugate-targeting-trop2-and-c-met-for-low-concentration-single-dose-treatment-of-pancreatic-cancer/355627/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-bispecific-nanobody-drug-conjugate-targeting-trop2-and-c-met-for-low-concentration-single-dose-treatment-of-pancreatic-cancer/355627.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is B6ADC and what targets does it bind?","Question",{"text":112,"@type":113},"B6ADC is a nanobody-based bispecific ADC designed to simultaneously target TROP2 and c-Met.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does B6ADC perform in preclinical models?",{"text":117,"@type":113},"B6ADC shows potent cytotoxicity in vitro across TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination approaches.",{"name":119,"@type":110,"acceptedAnswer":120},"What dosing result is highlighted for pancreatic cancer models?",{"text":121,"@type":113},"A single dose at a low concentration of 2.2 mg/kg eradicates giant tumors in the reported preclinical setting.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355627,1790795490,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Article  \nA bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer  \nAuthors  \nWenjing Ning, Han Liu, Hongye Zeng, ..., Ningshao Xia, Xue Liu, Wenxin Luo  \nCorrespondence  \n[yuanzhichen@xmu.edu.cn](yuanzhichen@xmu.edu.cn) (Y.C.),  \n[nsxia@xmu.edu.cn](nsxia@xmu.edu.cn) (N.X.),  \n[liuxue1108@xmu.edu.cn](liuxue1108@xmu.edu.cn) (X.L.),  \n[wxluo@xmu.edu.cn](wxluo@xmu.edu.cn) (W.L.)  \nIn brief  \nNing et al. develop a nanobody-based bispecific ADC (B6ADC) that simultaneously targets TROP2 and cMet. B6ADC demonstrates potent antitumor activity in preclinical models and offers a promising therapeutic strategy for pancreatic cancer and other TROP2/c-Met-expressing malignancies.  \n• TROP2/c-Met bispecific ADC (B6ADC) shows potent efficacy in pancreatic cancer models  \n• B6ADC demonstrates broad antitumor efficacy and eradicates giant tumors  \n• B6ADC has a favorable safety profile  \nNing et al., 2026, Cell Reports Medicine 7, 102688  \nApril 21, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102688](https://doi.org/10.1016/j.xcrm.2026.102688)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nA bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer  \nWenjing Ning,1,2,4 Han Liu,1,2,4 Hongye Zeng,1,2,4 Xiaojing Qin,1,2,4 Lin Xu,1,2 Shiting Yang,1,2 Yue Wang,1,2 Fentian Chen,1,2 Na Yuan,1,2 Xiaoqing Chen,1,2 Tao Xu,1,2 Kexin Wu,1,2 Peng Wang,1,2 Chao Liu,3 Yuanzhi Chen,1,2,* Ningshao Xia,1,2,* Xue Liu,1,2,* and Wenxin Luo1,2,5,*  \n1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China  \n2National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen 361102, China  \n3State Key Laboratory of Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China  \n4These authors contributed equally  \n5Lead contact  \n*Correspondence: [yuanzhichen@xmu.edu.cn](yuanzhichen@xmu.edu.cn) (Y.C.), [nsxia@xmu.edu.cn](nsxia@xmu.edu.cn) (N.X.), liuxue1[108@xmu.edu.cn](108@xmu.edu.cn) (X. L.), [wxluo@xmu.edu.cn](wxluo@xmu.edu.cn) (W. L.) [https://doi.org/10.1016/j.xcrm.2026.102688](https://doi.org/10.1016/j.xcrm.2026.102688)  \nSUMMARY  \nPancreatic cancer remains highly lethal with limited treatment options. Although antibody-drug conjugates (ADCs) have emerged as promising therapeutic agents, their efficacy is often limited by heterogeneous antigen expression and poor tumor penetration. To address these limitations, we develop B6ADC, a nanobodybased bispecific ADC that simultaneously targets TROP2 and c-Met. In preclinical studies, B6ADC exhibits potent cytotoxicity in vitro across various TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination, including the clinically approved TROP2 ADC sacituzumab govitecan and c-Met ADC Teliso-V, as well as their combination. Notably, B6ADC eradicates giant tumors with a single dose at a low concentration of 2.2 mg/kg. We present a nanobody-based BsADC that simultaneously targetsTROP2 and c-Met, with broad-spectrum antitumor activity, and improves selectivity for tumors with dual-positive or weakly positive antigen expression, offering a promising strategy for treating pancreatic cancer and other TROP2/c-Met-expressing malignancies.  \nINTRODUCTION  \nMalignant tumors represent a major global public health crisis, posing a severe threat to human health. Pancreatic cancer, which is often referred to as the ‘‘king of cancers,’’ remains one of the most lethal malignanci","cbCaicMtj3oVZ54E","https://ap.wps.com/l/cbCaicMtj3oVZ54E","pdf",18139992,24,"English","# Summary\n# Introduction\n## Challenges in current ADC therapy\n## Rationale for bispecific ADCs in pancreatic cancer","[{\"question\":\"What is B6ADC and what targets does it bind?\",\"answer\":\"B6ADC is a nanobody-based bispecific ADC designed to simultaneously target TROP2 and c-Met.\"},{\"question\":\"How does B6ADC perform in preclinical models?\",\"answer\":\"B6ADC shows potent cytotoxicity in vitro across TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination approaches.\"},{\"question\":\"What dosing result is highlighted for pancreatic cancer models?\",\"answer\":\"A single dose at a low concentration of 2.2 mg/kg eradicates giant tumors in the reported preclinical setting.\"}]","A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer | PDF",1790120208,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67d8f7946c19a8a9cf1947e0745fad0c.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db07f06877a10ec41507a689bd204312.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f65aaa46116aebbbd58c7719bb5afcb8.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ba22a2a9f96588d0b0573ef0bb519fb.webp",980,1272]